119 related articles for article (PubMed ID: 38156920)
1. EGFR-targeting peptide conjugated polymer-lipid hybrid nanoparticles for delivery of salinomycin to osteosarcoma.
Du L; Xu Y; Han B; Wang Y; Zeng Q; Shao M; Yu Z
J Cancer Res Ther; 2023 Dec; 19(6):1544-1551. PubMed ID: 38156920
[TBL] [Abstract][Full Text] [Related]
2. Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells.
Ni M; Xiong M; Zhang X; Cai G; Chen H; Zeng Q; Yu Z
Int J Nanomedicine; 2015; 10():2537-54. PubMed ID: 25848270
[TBL] [Abstract][Full Text] [Related]
3. GE11 Modified PLGA/TPGS Nanoparticles Targeting Delivery of Salinomycin to Breast Cancer Cells.
Li K; Pang L; Pan X; Fan S; Wang X; Wang Q; Dai P; Gao W; Gao J
Technol Cancer Res Treat; 2021; 20():15330338211004954. PubMed ID: 34056977
[TBL] [Abstract][Full Text] [Related]
4. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways.
Pi J; Jiang J; Cai H; Yang F; Jin H; Yang P; Cai J; Chen ZW
Drug Deliv; 2017 Nov; 24(1):1549-1564. PubMed ID: 29019267
[TBL] [Abstract][Full Text] [Related]
5. Salinomycin-loaded PLA nanoparticles: drug quantification by GPC and wave voltammetry and biological studies on osteosarcoma cancer stem cells.
Mineo PG; Foti C; Vento F; Montesi M; Panseri S; Piperno A; Scala A
Anal Bioanal Chem; 2020 Jul; 412(19):4681-4690. PubMed ID: 32451642
[TBL] [Abstract][Full Text] [Related]
6. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
7. Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells.
Chen F; Zeng Y; Qi X; Chen Y; Ge Z; Jiang Z; Zhang X; Dong Y; Chen H; Yu Z
Nanomedicine; 2018 Oct; 14(7):2115-2127. PubMed ID: 29898423
[TBL] [Abstract][Full Text] [Related]
8. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation.
Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW
Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009
[TBL] [Abstract][Full Text] [Related]
9. Intra-Articular Formulation of GE11-PLGA Conjugate-Based NPs for Dexamethasone Selective Targeting-In Vitro Evaluation.
Chiesa E; Pisani S; Colzani B; Dorati R; Conti B; Modena T; Braekmans K; Genta I
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30082640
[TBL] [Abstract][Full Text] [Related]
10. Enhanced and Prolonged Antitumor Effect of Salinomycin-Loaded Gelatinase-Responsive Nanoparticles via Targeted Drug Delivery and Inhibition of Cervical Cancer Stem Cells.
Wang Q; Liu F; Wang L; Xie C; Wu P; Du S; Zhou S; Sun Z; Liu Q; Yu L; Liu B; Li R
Int J Nanomedicine; 2020; 15():1283-1295. PubMed ID: 32161458
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression.
Go G; Park HJ; Lee JH; Yun CW; Lee SH
Anticancer Res; 2022 Feb; 42(2):857-866. PubMed ID: 35093883
[TBL] [Abstract][Full Text] [Related]
12. Design of smart GE11-PLGA/PEG-PLGA blend nanoparticulate platforms for parenteral administration of hydrophilic macromolecular drugs: synthesis, preparation and in vitro/ex vivo characterization.
Colzani B; Speranza G; Dorati R; Conti B; Modena T; Bruni G; Zagato E; Vermeulen L; Dakwar GR; Braeckmans K; Genta I
Int J Pharm; 2016 Sep; 511(2):1112-23. PubMed ID: 27511710
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor aptamer-conjugated polymer-lipid hybrid nanoparticles enhance salinomycin delivery to osteosarcoma and cancer stem cells.
Yu Z; Chen F; Qi X; Dong Y; Zhang Y; Ge Z; Cai G; Zhang X
Exp Ther Med; 2018 Feb; 15(2):1247-1256. PubMed ID: 29399118
[TBL] [Abstract][Full Text] [Related]
14. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
[TBL] [Abstract][Full Text] [Related]
15. Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment.
Hailing T; Yonghong P; Yufeng Z; Haitao T
J Control Release; 2022 Sep; 349():592-605. PubMed ID: 35872181
[TBL] [Abstract][Full Text] [Related]
16. Hybrid Cell Membrane-Functionalized Biomimetic Nanoparticles for Targeted Therapy of Osteosarcoma.
Cai JX; Liu JH; Wu JY; Li YJ; Qiu XH; Xu WJ; Xu P; Xiang DX
Int J Nanomedicine; 2022; 17():837-854. PubMed ID: 35228800
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of growth factor receptor-bound protein 2/epidermal growth factor receptor dual-targeting peptide inhibitor and salinomycin on osteosarcoma.
Yu Z; Xu Y; Du L; Zhang F; Shao M; Xie L; Cai G; Lyu F
J Cancer Res Ther; 2022 Apr; 18(2):352-361. PubMed ID: 35645100
[TBL] [Abstract][Full Text] [Related]
18. Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.
Zeng YB; Yu ZC; He YN; Zhang T; Du LB; Dong YM; Chen HW; Zhang YY; Wang WQ
Acta Pharmacol Sin; 2018 Feb; 39(2):261-274. PubMed ID: 29388568
[TBL] [Abstract][Full Text] [Related]
19. Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity.
Dong Z; Wang Y; Guo J; Tian C; Pan W; Wang H; Yan J
Drug Des Devel Ther; 2022; 16():2683-2693. PubMed ID: 35983428
[TBL] [Abstract][Full Text] [Related]
20. F3 peptide functionalized liquid crystalline nanoparticles for delivering Salinomycin against breast cancer.
Kumar H; Gupta NV; Jain R; Madhunapantula SV; Babu S; Dey S; Soni AG; Jain V
Int J Pharm; 2023 Aug; 643():123226. PubMed ID: 37451328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
